Gyre Therapeutics - Public Comps and Valuation Multiples

Gyre Therapeutics Overview

About Gyre Therapeutics

Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.

Founded

1997

HQ

Employees

579

Website

gyretx.com

Sectors

Small Molecules

Financials

LTM Revenue $117M

Last FY EBITDA $17.8M

EV

$658M

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Gyre Therapeutics Financials

As of August 2025, Gyre Therapeutics reported last 12-month revenue of $117M.

In the same period, Gyre Therapeutics achieved $15.8M in LTM net income.

See Gyre Therapeutics valuation multiples based on analyst estimates

Gyre Therapeutics P&L

In the most recent fiscal year, Gyre Therapeutics reported revenue of $106M and EBITDA of $17.8M.

Gyre Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Gyre Therapeutics valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$117M	XXX	$106M	XXX	XXX	XXX
Gross Profit	n/a	XXX	$102M	XXX	XXX	XXX
Gross Margin	n/a	XXX	96%	XXX	XXX	XXX
EBITDA	n/a	XXX	$17.8M	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	17%	XXX	XXX	XXX
EBIT	n/a	XXX	$16.2M	XXX	XXX	XXX
EBIT Margin	n/a	XXX	15%	XXX	XXX	XXX
Net Profit	$15.8M	XXX	$12.1M	XXX	XXX	XXX
Net Margin	14%	XXX	11%	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Gyre Therapeutics including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $117M. In the most recent fiscal year, Gyre Therapeutics achieved $106M in revenue and $17.8M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$117M	Analyst estimates available to subscribers	$106M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	n/a	Analyst estimates available to subscribers	$102M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	n/a	Analyst estimates available to subscribers	96.3% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	n/a	Analyst estimates available to subscribers	$17.8M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	n/a	Analyst estimates available to subscribers	16.8% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	n/a	Analyst estimates available to subscribers	$16.2M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	n/a	Analyst estimates available to subscribers	15.3% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$15.8M	Analyst estimates available to subscribers	$12.1M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	13.5% net profit margin	Analyst estimates available to subscribers	11.4% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Gyre Therapeutics

This financial data table provides comprehensive performance metrics for Gyre Therapeutics, a company based in United States of America. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Gyre Therapeutics generated $117M in revenue over the last twelve months.
Net income over the last twelve months reached $15.8M.

Fiscal Year Performance

In the most recent fiscal year, Gyre Therapeutics reported $106M in total revenue.
Fiscal year EBITDA was $17.8M.
The company maintained a gross profit margin of 96.3% in the most recent fiscal year.
EBITDA margin for the fiscal year was 16.8%.
Net profit margin reached 11.4% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Gyre Therapeutics. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Gyre Therapeutics Stock Performance

Gyre Therapeutics has current market cap of $711M, and EV of $658M.

Market Cap Evolution

Gyre Therapeutics Stock Data

As of September 12, 2025, Gyre Therapeutics's stock price is $8.

See Gyre Therapeutics trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$658M	$711M	XXX	XXX	XXX	XXX	$0.11

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Gyre Therapeutics Valuation Multiples

Gyre Therapeutics's trades at 6.2x EV/Revenue multiple, and 36.9x EV/EBITDA.

See valuation multiples for Gyre Therapeutics and 15K+ public comps

Gyre Therapeutics Financial Valuation Multiples

As of September 12, 2025, Gyre Therapeutics has market cap of $711M and EV of $658M.

Equity research analysts estimate Gyre Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Gyre Therapeutics has a P/E ratio of 45.1x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$711M	XXX	$711M	XXX	XXX	XXX
EV (current)	$658M	XXX	$658M	XXX	XXX	XXX
EV/Revenue	5.6x	XXX	6.2x	XXX	XXX	XXX
EV/EBITDA	n/a	XXX	36.9x	XXX	XXX	XXX
EV/EBIT	n/a	XXX	40.6x	XXX	XXX	XXX
EV/Gross Profit	n/a	XXX	n/a	XXX	XXX	XXX
P/E	45.1x	XXX	58.8x	XXX	XXX	XXX
EV/FCF	n/a	XXX	-97.2x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Gyre Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Gyre Therapeutics Margins & Growth Rates

Gyre Therapeutics's last 12 month revenue growth is 41%

Gyre Therapeutics's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.

Gyre Therapeutics's rule of 40 is 59% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Gyre Therapeutics's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Gyre Therapeutics and other 15K+ public comps

Gyre Therapeutics Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	41%	XXX	31%	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	17%	XXX	XXX	XXX
EBITDA Growth	n/a	XXX	-4%	XXX	XXX	XXX
Rule of 40	59%	XXX	58%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	n/a	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.2M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.1M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	54%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	11%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	81%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial